Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Lymphocytic, Chronic, B-Cell | 114 | 2025 | 1646 | 19.100 |
Why?
|
Sulfonamides | 46 | 2025 | 1984 | 6.120 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 33 | 2025 | 1410 | 5.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 45 | 2024 | 11868 | 2.940 |
Why?
|
Benzamides | 9 | 2024 | 1377 | 2.890 |
Why?
|
Pyrazines | 8 | 2024 | 1204 | 2.790 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 13 | 2024 | 1434 | 2.730 |
Why?
|
Pyrimidines | 27 | 2024 | 3047 | 2.650 |
Why?
|
Antineoplastic Agents | 43 | 2025 | 13648 | 2.630 |
Why?
|
Pyrazoles | 21 | 2024 | 2033 | 2.540 |
Why?
|
Hematologic Neoplasms | 11 | 2024 | 1927 | 2.030 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 3 | 2021 | 180 | 1.990 |
Why?
|
Piperidines | 24 | 2024 | 1664 | 1.980 |
Why?
|
Adenine | 21 | 2024 | 994 | 1.970 |
Why?
|
Quinazolinones | 9 | 2024 | 219 | 1.960 |
Why?
|
Lymphoma, Mantle-Cell | 8 | 2021 | 238 | 1.960 |
Why?
|
Purines | 14 | 2024 | 615 | 1.900 |
Why?
|
Protein Kinase Inhibitors | 24 | 2024 | 5696 | 1.780 |
Why?
|
Vidarabine | 5 | 2024 | 343 | 1.710 |
Why?
|
Lymphoma, Non-Hodgkin | 6 | 2023 | 1376 | 1.610 |
Why?
|
Molecular Targeted Therapy | 12 | 2025 | 2822 | 1.580 |
Why?
|
Lymphoma, Follicular | 5 | 2023 | 459 | 1.260 |
Why?
|
Apoptosis | 20 | 2025 | 9514 | 1.210 |
Why?
|
Phosphatidylinositol 3-Kinases | 8 | 2024 | 2878 | 1.190 |
Why?
|
Drug Resistance, Neoplasm | 22 | 2025 | 5337 | 1.160 |
Why?
|
Protein-Tyrosine Kinases | 7 | 2017 | 2423 | 1.160 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 3 | 2024 | 23 | 1.130 |
Why?
|
Chromosome Deletion | 10 | 2024 | 1385 | 1.070 |
Why?
|
Cyclophosphamide | 7 | 2024 | 2228 | 1.020 |
Why?
|
Chromosomes, Human, Pair 17 | 6 | 2018 | 416 | 1.020 |
Why?
|
Lymphoma, B-Cell | 7 | 2024 | 943 | 1.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 15 | 2023 | 5753 | 0.870 |
Why?
|
Isoquinolines | 6 | 2024 | 350 | 0.850 |
Why?
|
Lymphoma | 7 | 2024 | 1897 | 0.780 |
Why?
|
Neoplasm Proteins | 6 | 2024 | 3596 | 0.750 |
Why?
|
Humans | 175 | 2025 | 765968 | 0.700 |
Why?
|
Splenic Neoplasms | 1 | 2021 | 97 | 0.700 |
Why?
|
Recurrence | 14 | 2024 | 8501 | 0.690 |
Why?
|
Receptors, Antigen, B-Cell | 4 | 2019 | 545 | 0.680 |
Why?
|
Pneumocystis carinii | 1 | 2020 | 70 | 0.650 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1774 | 0.650 |
Why?
|
Smith-Magenis Syndrome | 5 | 2018 | 19 | 0.640 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2020 | 239 | 0.610 |
Why?
|
Bone Marrow Diseases | 2 | 2010 | 234 | 0.600 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2017 | 58 | 0.560 |
Why?
|
Stromal Cells | 2 | 2013 | 1329 | 0.560 |
Why?
|
Hematology | 1 | 2021 | 243 | 0.560 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2021 | 2505 | 0.560 |
Why?
|
Opportunistic Infections | 1 | 2020 | 376 | 0.550 |
Why?
|
Waldenstrom Macroglobulinemia | 3 | 2021 | 1076 | 0.550 |
Why?
|
Aged | 67 | 2024 | 171117 | 0.530 |
Why?
|
Aged, 80 and over | 42 | 2024 | 59489 | 0.530 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2019 | 2942 | 0.520 |
Why?
|
Signal Transduction | 12 | 2025 | 23601 | 0.470 |
Why?
|
Neutropenia | 4 | 2023 | 893 | 0.470 |
Why?
|
Mitochondria | 7 | 2020 | 3673 | 0.450 |
Why?
|
MAP Kinase Signaling System | 1 | 2021 | 1490 | 0.450 |
Why?
|
Sequence Deletion | 1 | 2018 | 1495 | 0.450 |
Why?
|
Radioactive Hazard Release | 2 | 2010 | 13 | 0.440 |
Why?
|
Chromosomes, Human | 1 | 2015 | 437 | 0.420 |
Why?
|
Middle Aged | 61 | 2024 | 223009 | 0.420 |
Why?
|
Safety | 1 | 2017 | 1157 | 0.410 |
Why?
|
Treatment Outcome | 29 | 2024 | 65188 | 0.400 |
Why?
|
Irritable Bowel Syndrome | 1 | 2017 | 454 | 0.390 |
Why?
|
Gastrointestinal Tract | 1 | 2018 | 834 | 0.390 |
Why?
|
Lymphoproliferative Disorders | 1 | 2016 | 526 | 0.390 |
Why?
|
Male | 69 | 2024 | 363698 | 0.380 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 2023 | 3646 | 0.360 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2010 | 91 | 0.350 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2010 | 15 | 0.350 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2010 | 84 | 0.350 |
Why?
|
Stem Cell Transplantation | 4 | 2023 | 1602 | 0.350 |
Why?
|
Mutation | 16 | 2024 | 30198 | 0.350 |
Why?
|
Remission Induction | 7 | 2021 | 2411 | 0.340 |
Why?
|
Nuclear Weapons | 1 | 2010 | 12 | 0.340 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2010 | 172 | 0.340 |
Why?
|
Female | 68 | 2024 | 396112 | 0.340 |
Why?
|
Drug Administration Schedule | 6 | 2021 | 4850 | 0.330 |
Why?
|
Disease-Free Survival | 12 | 2022 | 6832 | 0.330 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9373 | 0.320 |
Why?
|
Warfarin | 1 | 2017 | 1494 | 0.320 |
Why?
|
Databases, Factual | 1 | 2024 | 8067 | 0.310 |
Why?
|
Aniline Compounds | 3 | 2024 | 1075 | 0.310 |
Why?
|
Antigens, CD20 | 2 | 2021 | 198 | 0.300 |
Why?
|
Haploinsufficiency | 1 | 2010 | 334 | 0.300 |
Why?
|
Survival Rate | 11 | 2022 | 12795 | 0.300 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2024 | 904 | 0.300 |
Why?
|
Adult | 49 | 2024 | 223044 | 0.290 |
Why?
|
bcl-X Protein | 3 | 2025 | 414 | 0.290 |
Why?
|
Administration, Oral | 5 | 2019 | 4015 | 0.290 |
Why?
|
Patient Simulation | 1 | 2010 | 301 | 0.290 |
Why?
|
Mass Casualty Incidents | 1 | 2010 | 178 | 0.290 |
Why?
|
Renal Dialysis | 1 | 2017 | 1799 | 0.290 |
Why?
|
Cell Line, Tumor | 12 | 2025 | 17075 | 0.280 |
Why?
|
Disaster Planning | 2 | 2010 | 559 | 0.280 |
Why?
|
Terrorism | 1 | 2010 | 211 | 0.280 |
Why?
|
Antibodies, Monoclonal | 6 | 2024 | 9249 | 0.280 |
Why?
|
Neoplasm, Residual | 6 | 2023 | 1009 | 0.280 |
Why?
|
Gene Expression Regulation, Leukemic | 5 | 2021 | 657 | 0.270 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2014 | 328 | 0.260 |
Why?
|
Salvage Therapy | 3 | 2020 | 1272 | 0.250 |
Why?
|
Graft vs Host Disease | 5 | 2020 | 3078 | 0.250 |
Why?
|
Neoplasms | 7 | 2025 | 22340 | 0.250 |
Why?
|
Bone Marrow Transplantation | 2 | 2010 | 2729 | 0.240 |
Why?
|
Cell Communication | 1 | 2012 | 1660 | 0.240 |
Why?
|
Prognosis | 15 | 2024 | 29922 | 0.240 |
Why?
|
Transplantation, Homologous | 5 | 2019 | 4860 | 0.240 |
Why?
|
B-Lymphocytes | 3 | 2023 | 4778 | 0.240 |
Why?
|
Thionucleotides | 2 | 2017 | 108 | 0.240 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2018 | 330 | 0.230 |
Why?
|
Nitriles | 2 | 2021 | 982 | 0.230 |
Why?
|
Lymphocytes | 1 | 2012 | 2599 | 0.230 |
Why?
|
Leukemia | 3 | 2018 | 1522 | 0.230 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2023 | 1151 | 0.230 |
Why?
|
Follow-Up Studies | 9 | 2024 | 39193 | 0.230 |
Why?
|
Immunologic Deficiency Syndromes | 2 | 2024 | 548 | 0.220 |
Why?
|
Hodgkin Disease | 2 | 2021 | 1383 | 0.220 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 2310 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 5 | 2018 | 4520 | 0.210 |
Why?
|
Doxorubicin | 4 | 2024 | 2230 | 0.210 |
Why?
|
Etoposide | 2 | 2022 | 636 | 0.210 |
Why?
|
Receptors, CXCR4 | 3 | 2021 | 728 | 0.210 |
Why?
|
Clinical Trials as Topic | 5 | 2024 | 8041 | 0.210 |
Why?
|
Vincristine | 2 | 2024 | 1039 | 0.210 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2024 | 371 | 0.210 |
Why?
|
Myelodysplastic Syndromes | 2 | 2023 | 1404 | 0.210 |
Why?
|
Radiation Injuries | 1 | 2010 | 1181 | 0.200 |
Why?
|
Cost of Illness | 2 | 2024 | 1950 | 0.200 |
Why?
|
Chemokine CXCL12 | 2 | 2016 | 455 | 0.200 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3715 | 0.200 |
Why?
|
Health Services Needs and Demand | 1 | 2010 | 1406 | 0.200 |
Why?
|
Ribosomal Proteins | 1 | 2024 | 366 | 0.190 |
Why?
|
Pseudopseudohypoparathyroidism | 1 | 2001 | 8 | 0.190 |
Why?
|
Leukemia, Prolymphocytic | 1 | 2021 | 7 | 0.190 |
Why?
|
Animals | 22 | 2025 | 168764 | 0.190 |
Why?
|
TNF Receptor-Associated Factor 4 | 1 | 2021 | 5 | 0.190 |
Why?
|
Immunoglobulin Heavy Chains | 3 | 2019 | 648 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-bcr | 1 | 2021 | 21 | 0.190 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2024 | 8611 | 0.180 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2021 | 720 | 0.180 |
Why?
|
Antigens, CD19 | 1 | 2024 | 443 | 0.180 |
Why?
|
Pyrimethamine | 1 | 2021 | 95 | 0.180 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2025 | 3608 | 0.180 |
Why?
|
Chlorambucil | 1 | 2020 | 42 | 0.170 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2023 | 3111 | 0.170 |
Why?
|
Transplantation, Autologous | 6 | 2023 | 2120 | 0.170 |
Why?
|
Tumor Lysis Syndrome | 2 | 2017 | 37 | 0.170 |
Why?
|
Cytogenetics | 2 | 2017 | 198 | 0.170 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2025 | 752 | 0.170 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 42 | 0.160 |
Why?
|
Prednisone | 2 | 2022 | 1565 | 0.160 |
Why?
|
Myeloproliferative Disorders | 2 | 2016 | 616 | 0.160 |
Why?
|
Atrial Fibrillation | 1 | 2017 | 5189 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2024 | 2453 | 0.160 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2014 | 1333 | 0.150 |
Why?
|
Pyrroles | 2 | 2017 | 1119 | 0.150 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3100 | 0.150 |
Why?
|
Retrospective Studies | 16 | 2024 | 81514 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3223 | 0.150 |
Why?
|
Epoxy Compounds | 1 | 2018 | 136 | 0.150 |
Why?
|
Quinazolines | 1 | 2024 | 1364 | 0.150 |
Why?
|
Retreatment | 1 | 2019 | 598 | 0.150 |
Why?
|
Peptide Fragments | 3 | 2017 | 5125 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6499 | 0.140 |
Why?
|
Macrolides | 1 | 2018 | 204 | 0.140 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2021 | 587 | 0.140 |
Why?
|
Disease Progression | 9 | 2023 | 13632 | 0.140 |
Why?
|
Gossypol | 1 | 2017 | 23 | 0.140 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2023 | 2056 | 0.140 |
Why?
|
Lymphocytosis | 1 | 2018 | 120 | 0.140 |
Why?
|
Methylprednisolone | 1 | 2018 | 386 | 0.140 |
Why?
|
Tumor Microenvironment | 3 | 2025 | 3946 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 870 | 0.130 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2023 | 2844 | 0.130 |
Why?
|
Indoles | 2 | 2017 | 1839 | 0.130 |
Why?
|
Th17 Cells | 1 | 2023 | 786 | 0.130 |
Why?
|
Mice | 12 | 2025 | 81819 | 0.130 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 93 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 190 | 0.130 |
Why?
|
Piperazines | 4 | 2016 | 2549 | 0.130 |
Why?
|
Virus Activation | 1 | 2018 | 323 | 0.130 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8529 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2021 | 811 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 639 | 0.120 |
Why?
|
Drug Synergism | 2 | 2017 | 1749 | 0.120 |
Why?
|
DNA Mutational Analysis | 2 | 2017 | 4108 | 0.120 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1171 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2021 | 995 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
Oxidative Stress | 2 | 2020 | 3141 | 0.120 |
Why?
|
Hematologic Diseases | 1 | 2019 | 500 | 0.120 |
Why?
|
Immunotherapy | 4 | 2023 | 4752 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 4642 | 0.120 |
Why?
|
Nitrophenols | 2 | 2012 | 169 | 0.120 |
Why?
|
Exanthema | 1 | 2019 | 502 | 0.120 |
Why?
|
Neoplasm Staging | 6 | 2020 | 11206 | 0.120 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 1737 | 0.120 |
Why?
|
Scleroderma, Diffuse | 1 | 2014 | 18 | 0.120 |
Why?
|
Interleukin-6 | 1 | 2024 | 3222 | 0.120 |
Why?
|
Time Factors | 6 | 2021 | 40065 | 0.120 |
Why?
|
DNA Damage | 2 | 2021 | 2457 | 0.110 |
Why?
|
Karyotyping | 1 | 2016 | 1178 | 0.110 |
Why?
|
Hepatitis B virus | 1 | 2018 | 530 | 0.110 |
Why?
|
Antigens, CD | 1 | 2024 | 4025 | 0.110 |
Why?
|
Transplantation Immunology | 1 | 2016 | 541 | 0.110 |
Why?
|
United States | 10 | 2021 | 72903 | 0.110 |
Why?
|
Skin Neoplasms | 2 | 2014 | 5849 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1510 | 0.110 |
Why?
|
Treatment Failure | 1 | 2020 | 2652 | 0.110 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1808 | 0.110 |
Why?
|
Anemia | 1 | 2023 | 1511 | 0.110 |
Why?
|
Autoimmunity | 1 | 2021 | 1354 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 2021 | 10261 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.110 |
Why?
|
Alternative Splicing | 1 | 2018 | 1107 | 0.110 |
Why?
|
Bone Marrow | 2 | 2020 | 2921 | 0.110 |
Why?
|
Tumor Cells, Cultured | 3 | 2021 | 6113 | 0.100 |
Why?
|
Antifungal Agents | 1 | 2018 | 769 | 0.100 |
Why?
|
Quinoxalines | 1 | 2015 | 296 | 0.100 |
Why?
|
Triazoles | 1 | 2018 | 897 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2020 | 2424 | 0.100 |
Why?
|
Registries | 4 | 2020 | 8297 | 0.100 |
Why?
|
Hepatitis B | 1 | 2018 | 707 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2354 | 0.100 |
Why?
|
Transplantation Conditioning | 2 | 2019 | 1635 | 0.100 |
Why?
|
Antiviral Agents | 2 | 2021 | 3050 | 0.100 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2001 | 1833 | 0.100 |
Why?
|
Lymph Nodes | 2 | 2014 | 3454 | 0.090 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2012 | 292 | 0.090 |
Why?
|
Comorbidity | 4 | 2020 | 10563 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1555 | 0.090 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2012 | 340 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 10729 | 0.090 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 1224 | 0.090 |
Why?
|
Bence Jones Protein | 1 | 2010 | 19 | 0.090 |
Why?
|
Blood Protein Electrophoresis | 1 | 2010 | 65 | 0.090 |
Why?
|
Myeloma Proteins | 1 | 2010 | 71 | 0.090 |
Why?
|
Densitometry | 1 | 2010 | 150 | 0.090 |
Why?
|
Boston | 2 | 2021 | 9338 | 0.090 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2012 | 429 | 0.090 |
Why?
|
Biphenyl Compounds | 2 | 2012 | 1019 | 0.090 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2587 | 0.080 |
Why?
|
Government Agencies | 1 | 2010 | 161 | 0.080 |
Why?
|
Immunoglobulin Variable Region | 2 | 2023 | 419 | 0.080 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2010 | 86 | 0.080 |
Why?
|
Fatal Outcome | 2 | 2017 | 1831 | 0.080 |
Why?
|
Half-Life | 1 | 2010 | 644 | 0.080 |
Why?
|
Blood Banks | 1 | 2010 | 108 | 0.080 |
Why?
|
Myocarditis | 1 | 2017 | 802 | 0.080 |
Why?
|
Serum | 1 | 2010 | 206 | 0.080 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2009 | 127 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 200 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 10383 | 0.080 |
Why?
|
Interinstitutional Relations | 1 | 2010 | 234 | 0.080 |
Why?
|
Prospective Studies | 7 | 2022 | 54802 | 0.080 |
Why?
|
Relief Work | 1 | 2010 | 132 | 0.080 |
Why?
|
Health Planning | 1 | 2010 | 233 | 0.080 |
Why?
|
Survival Analysis | 5 | 2020 | 10070 | 0.080 |
Why?
|
Societies, Medical | 1 | 2021 | 3956 | 0.080 |
Why?
|
Civil Defense | 1 | 2010 | 114 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5526 | 0.080 |
Why?
|
Coculture Techniques | 1 | 2012 | 1336 | 0.080 |
Why?
|
Anemia, Aplastic | 1 | 2010 | 232 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13451 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2012 | 2880 | 0.070 |
Why?
|
Paraproteinemias | 1 | 2010 | 252 | 0.070 |
Why?
|
Keratins | 1 | 2009 | 498 | 0.070 |
Why?
|
Age Factors | 3 | 2020 | 18380 | 0.070 |
Why?
|
Abdomen | 1 | 2014 | 1134 | 0.070 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1528 | 0.070 |
Why?
|
Indazoles | 1 | 2009 | 303 | 0.070 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 368 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 950 | 0.070 |
Why?
|
Pyridines | 1 | 2018 | 2888 | 0.070 |
Why?
|
Scalp | 1 | 2009 | 388 | 0.070 |
Why?
|
BRCA2 Protein | 1 | 2011 | 800 | 0.060 |
Why?
|
Cytarabine | 2 | 2020 | 698 | 0.060 |
Why?
|
Pandemics | 3 | 2020 | 8703 | 0.060 |
Why?
|
Clone Cells | 2 | 2021 | 1672 | 0.060 |
Why?
|
Lung Diseases, Interstitial | 1 | 2014 | 939 | 0.060 |
Why?
|
Dendritic Cells | 1 | 2016 | 2747 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3785 | 0.060 |
Why?
|
Point Mutation | 1 | 2010 | 1590 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 2412 | 0.060 |
Why?
|
Oxidation-Reduction | 2 | 2021 | 2218 | 0.060 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6309 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1394 | 0.060 |
Why?
|
BRCA1 Protein | 1 | 2011 | 1153 | 0.060 |
Why?
|
Maytansine | 1 | 2024 | 87 | 0.060 |
Why?
|
Myocardium | 1 | 2017 | 4760 | 0.060 |
Why?
|
International Cooperation | 1 | 2010 | 1432 | 0.050 |
Why?
|
Academic Medical Centers | 2 | 2014 | 2780 | 0.050 |
Why?
|
Chemokine CCL4 | 1 | 2023 | 124 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3251 | 0.050 |
Why?
|
Cause of Death | 1 | 2014 | 3708 | 0.050 |
Why?
|
Fetal Blood | 1 | 2010 | 1369 | 0.050 |
Why?
|
Protein Biosynthesis | 1 | 2010 | 2086 | 0.050 |
Why?
|
Triage | 1 | 2010 | 996 | 0.050 |
Why?
|
Amyloidosis | 1 | 2010 | 885 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2023 | 522 | 0.050 |
Why?
|
Muridae | 1 | 2001 | 55 | 0.050 |
Why?
|
Phosphorylation | 2 | 2024 | 8278 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2019 | 1866 | 0.050 |
Why?
|
Cohort Studies | 4 | 2017 | 41649 | 0.050 |
Why?
|
STAT6 Transcription Factor | 1 | 2021 | 197 | 0.050 |
Why?
|
Azacitidine | 1 | 2023 | 334 | 0.050 |
Why?
|
DNA Repair | 1 | 2010 | 2048 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2024 | 3655 | 0.040 |
Why?
|
Bleomycin | 1 | 2021 | 491 | 0.040 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2001 | 313 | 0.040 |
Why?
|
Vinblastine | 1 | 2021 | 483 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2001 | 252 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 691 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2023 | 497 | 0.040 |
Why?
|
Cell Proliferation | 3 | 2021 | 10429 | 0.040 |
Why?
|
Disease Management | 2 | 2021 | 2535 | 0.040 |
Why?
|
DNA | 1 | 2013 | 7202 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9525 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2020 | 737 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Dacarbazine | 1 | 2021 | 552 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2009 | 4893 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2010 | 1938 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 246 | 0.040 |
Why?
|
Protein Binding | 1 | 2010 | 9296 | 0.040 |
Why?
|
Base Sequence | 1 | 2009 | 12403 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 878 | 0.040 |
Why?
|
Spliceosomes | 1 | 2018 | 116 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 616 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 696 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2015 | 7851 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2021 | 1162 | 0.040 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2021 | 582 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1731 | 0.030 |
Why?
|
Oxidative Phosphorylation | 1 | 2019 | 502 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20659 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2024 | 981 | 0.030 |
Why?
|
Serine | 1 | 2020 | 824 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 2002 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1857 | 0.030 |
Why?
|
Models, Biological | 1 | 2012 | 9443 | 0.030 |
Why?
|
Young Adult | 6 | 2019 | 59889 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6547 | 0.030 |
Why?
|
Biopsy | 2 | 2019 | 6763 | 0.030 |
Why?
|
Mitogens | 1 | 2016 | 228 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2021 | 1144 | 0.030 |
Why?
|
Histiocytic Sarcoma | 1 | 2016 | 41 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1648 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2417 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2019 | 1602 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14652 | 0.030 |
Why?
|
Cell Transdifferentiation | 1 | 2016 | 186 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2016 | 705 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.030 |
Why?
|
Internationality | 1 | 2020 | 1007 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1658 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 898 | 0.030 |
Why?
|
Thiophenes | 1 | 2018 | 569 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2021 | 1275 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 170 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 360 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 711 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2001 | 4618 | 0.030 |
Why?
|
Cell Cycle | 1 | 2021 | 2920 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2045 | 0.030 |
Why?
|
Methylnitronitrosoguanidine | 1 | 2012 | 18 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 2140 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2025 | 18293 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2010 | 20124 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2023 | 5881 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2014 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 315 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1837 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2395 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2016 | 878 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 22332 | 0.020 |
Why?
|
Thalidomide | 1 | 2016 | 886 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 686 | 0.020 |
Why?
|
Inflammation | 2 | 2021 | 10850 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2013 | 790 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2936 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2021 | 5501 | 0.020 |
Why?
|
Biological Products | 1 | 2020 | 942 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 544 | 0.020 |
Why?
|
Founder Effect | 1 | 2011 | 185 | 0.020 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 431 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 14071 | 0.020 |
Why?
|
Chromatin | 1 | 2021 | 2980 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2018 | 2446 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2014 | 1693 | 0.020 |
Why?
|
Jews | 1 | 2011 | 357 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2014 | 553 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 17594 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1050 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2019 | 2892 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2014 | 2910 | 0.020 |
Why?
|
Up-Regulation | 1 | 2016 | 4137 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2573 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5747 | 0.020 |
Why?
|
Cell Death | 1 | 2012 | 1679 | 0.020 |
Why?
|
Health Care Costs | 1 | 2020 | 3242 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7421 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2021 | 12768 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2011 | 1153 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9550 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1899 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3602 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6203 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 24282 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2023 | 11641 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2011 | 18071 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5772 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2014 | 2132 | 0.010 |
Why?
|
Single-Cell Analysis | 1 | 2016 | 2535 | 0.010 |
Why?
|
Antirheumatic Agents | 1 | 2014 | 1365 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2018 | 12437 | 0.010 |
Why?
|
Tissue Donors | 1 | 2014 | 2395 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3106 | 0.010 |
Why?
|
Electrocardiography | 1 | 2017 | 6404 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2011 | 21056 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2012 | 2867 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2011 | 2242 | 0.010 |
Why?
|
Child | 1 | 2010 | 80564 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7584 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4255 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14448 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7425 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12056 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7562 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2011 | 2593 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6209 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12509 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9347 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4044 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16721 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 22223 | 0.010 |
Why?
|
Melanoma | 1 | 2014 | 5719 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15880 | 0.010 |
Why?
|
Adolescent | 1 | 2016 | 88835 | 0.000 |
Why?
|
Risk Factors | 1 | 2012 | 74840 | 0.000 |
Why?
|